Skip to main content
. 2011 Jan 20;342:d198. doi: 10.1136/bmj.d198

Table 3.

 Association between short term use of NSAIDs and risk of Parkinson’s disease in cases and matched controls from the Physicians’ Health Study

Days of use in prior year Odds ratio (95% CI)*
At index date 5 years prior†
Controls matched by age
Non-aspirin NSAID use:
 None 1.00 1.00
 1–14 0.84 (0.65 to 1.08) 1.11 (0.87 to 1.43)
 15–60 0.87 (0.64 to 1.18) 1.15 (0.86 to 1.55)
 >60 1.10 (0.81 to 1.50) 1.09 (0.76 to 1.55)
Aspirin use:
 None 1.00 1.00
 1–14 0.82 (0.56 to 1.18) 0.96 (0.66 to 1.41)
 15–60 1.15 (0.76 to 1.76) 1.12 (0.71 to 1.78)
 >60 0.92 (0.74 to 1.14) 0.93 (0.73 to 1.18)
Controls matched by age and confounder scores‡
Non-aspirin NSAID use:
 None 1.00 1.00
 1–14 0.82 (0.63 to 1.07) 1.05 (0.81 to 1.37)
 15–60 0.71 (0.51 to 0.99) 1.05 (0.76 to 1.45)
 >60 0.82 (0.59 to 1.14) 0.66 (0.44 to 1.00)
Aspirin use:
 None 1.00 1.00
 1–14 0.90 (0.60 to 1.34) 0.98 (0.64 to 1.48)
 15–60 1.29 (0.81 to 2.05) 1.23 (0.75 to 2.02)
 >60 0.99 (0.78 to 1.26) 0.98 (0.75 to 1.28)

*Estimated by conditional logistic regression. Analyses were adjusted for the following variables at time of matching: smoking (never, past, current), alcohol (daily, weekly, monthly), body mass index (<25, 25–<30, ≥30), exercise to sweat (ever v never). We adjusted for aspirin use when estimating effects of non-aspirin NSAIDS and vice versa.

†Excluding drug use within 5 years before the index date.

‡Confounder scores=modified Charlson comorbidity score, score for indicators of NSAID use, and score for NSAID side effects.